VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development at the company, will lead the advancement of VERAXA’s proprietary BiTAC(R) platform technologies for developing cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart after a transition period.
Erkel brings two decades of experience in antibody therapeutics, antibody engineering, and preclinical development. Prior to joining VERAXA, he held leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA stated that his experience managing multidisciplinary research programs will support efforts to expand the company’s oncology pipeline and advance BiTAC(R) candidates toward clinical development. The appointment underscores VERAXA’s commitment to strengthening its scientific leadership as it progresses its pipeline of bispecific T-cell engagers and antibody-drug conjugates (ADCs).
The BiTAC platform is a cornerstone of VERAXA’s strategy, aiming to improve therapeutic outcomes for patients with solid tumors. The company’s pipeline includes bispecific T-cell engagers, bispecific ADCs, and other innovative formats, all guided by quality-by-design principles. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company’s proprietary technologies are designed to address key challenges in oncology, such as tumor heterogeneity and immune evasion.
According to the press release, Erkel’s appointment comes at a critical time as VERAXA prepares to advance its lead candidates into clinical trials. The company believes his expertise in T-cell engagers will be instrumental in optimizing the BiTAC platform’s efficacy and safety profile. “Christoph’s deep knowledge of antibody engineering and immuno-oncology makes him the ideal leader to drive our scientific strategy forward,” said a company spokesperson. The transition period with outgoing CSO Rick Austin will ensure continuity in ongoing programs.
The full press release is available at https://nnw.fm/cR1RS. For more information about VERAXA and its pipeline, visit the company’s newsroom at https://ibn.fm/VRXA.
